This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Blockbuster Expectations Don't Always Translate To Market Reality

LONDON and BOSTON, April 9, 2013 /PRNewswire/ --

EP Vantage Analyzes Accuracy of Analyst Sales Estimates for Blockbuster and Near-Blockbuster Launches

Pharma industry observers widely expect Biogen Idec's new multiple sclerosis therapy Tecfidera to reach mega-blockbuster status. However, EP Vantage®, EvaluatePharma®'s award-winning editorial team cautions that forecasting revenue for an unlaunched drug isn't always easy. A five-year review of EvaluatePharma's consensus forecasts of analyst predictions for blockbuster or near-blockbuster drug launches found that new products with the biggest hopes often disappoint, while others have vastly outperformed low expectations.

The report, " The Industry's Brightest Hopes: Where Are They Now ?" uncovers some remarkable misses prompted by a sea change in treatment, reimbursement issues, safety concerns and heightened competition. While analysts' forecasts don't always ring true on performance, EP Vantage found that forecasts have also been spot on and in some cases performances even exceeded initial estimates.

"Evaluating the accuracy of consensus forecasts is particularly pertinent given the recent US approval of Tecfidera, with consensus data suggesting that this drug's sales could reach $3.7 billion within five years. Many factors can influence the success of a drug and while forecasts have been proven to ring true in many cases, our analysis shows just how far off they can be," commented Jacob Plieth, author of the EP Vantage report.

As the first company to provide consensus forecasts on global drug sales, EvaluatePharma takes the unweighted average of up to six equity research forecasts to provide reliable consensus estimates for the pharma and biotech industries to 2018. By taking an average, the impact of outlying forecasts is mitigated.

For a look at which of 2013's launches will be the next blockbusters, read the analysis here.

About EP Vantage

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,985.61 +78.99 0.47%
S&P 500 1,972.83 +9.12 0.46%
NASDAQ 4,419.0340 +27.5710 0.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs